- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01480778
Evaluation of Ciclo 21® Effect (Levonorgestrel + Ethinyl Estradiol) Compared to Nordette®.
March 2, 2016 updated by: Azidus Brasil
Pharmacodynamic Assessment to Drug Ciclo 21 (Levonorgestrel + Ethinyl Estradiol) Market by União Química Farmacêutica Nacional S/A Compared to Drug Nordette of Wieth Indústria Farmacêutica Ltda.
Assessment of the pharmacodynamic profile of the drug Ciclo 21 ®, marketed by União Química Farmacêutica Nacional S / A, compared to the drug Nordette ® Laboratory Wyeth Pharmaceutical Ltda.
Through the modulation of hormonal response (inhibition of the pituitary) evidenced by measurement serum LH and FSH for 28 days, as well as by the absence of follicle formation demonstrated by transvaginal ultrasound examinations
Study Overview
Detailed Description
secondary objective
- Evaluation of the safety aspects of medicines such as type, frequency and intensity of adverse events between groups during the 28 day trial.
exploratory objective
- Evaluation of the pharmacokinetics of the drug administered through the dosage of serum hormone levonorgestrel and ethinyl estradiol for 28 days.
Study Type
Interventional
Enrollment (Actual)
62
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
São Paulo
-
Valinhos, São Paulo, Brazil
- LAL Clínica Pesquisa e Desenvolvimento Ltda
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 35 years (ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Female
Description
Inclusion Criteria:
- Comply with all study procedures, sign, initial and date back, of their own free will, the IC;
- Women aged between 18 and 35 years, regardless of race and class;
- Make use of safe non-hormonal method of contraception such as tubal ligation, non-hormonal IUDs or condoms, or be hysterectomised or be vasectomized sexual partner;
- Examination of Beta-HCG negative;
- with regular menstrual cycles every 24 to 32 days, at least the last three months;
- present normal Pap test (current or during the past 02 years);
- Present or vaginal examination found that the changes do not interfere in the study;
- present levels of FSH, LH, estradiol and TT for the normal menstrual cycle, as well as normal transvaginal sonographic reports.
Exclusion Criteria:
- Provide a contraindication to the use of steroids;
- Use regular or prediction of drugs that interfere with the metabolism of the investigational products, such as antibiotics, anticonvulsants, anticoagulants and hypoglycemic drugs;
- smokers or have stopped smoking less than 12 months;
- Diabetic;
- Toxic-dependent;
- BMI <18 and> 25;
- have made use of topical or systemic sex hormone for at least two months before the start of the study;
- Background and personal or family history of thrombosis or bleeding disorders or vascular disorders or cardiovascular disease;
- Laboratory tests, gynecological ultrasound or changed, the medical criteria;
- Individuals with allergies or rheumatic diseases for which is indicated the use of cortico-steroid medication;
- carry any endocrine changes, especially pituitary and gonadal and / or who are advised to use hormones;
- with lesions or abnormalities suspected or confirmed in the gonads.
- personal or family history of breast cancer or other hormone-dependent breast pathology;
- with hypertension or diabetes mellitus (for drug interactions between the COC and hypoglycemic agents and antihypertensives);
a) History of nausea with oral use of COCs; p) Any condition that may interfere with the discretion of the investigator in the study data as well as being the measurement of the study be deleterious to the patient.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: LNG+EE2
pill test contained levonorgestrel 0,15 mg and ethynil estradiol 0,03 mg per day over 21 days
|
Administration of one pill contained 0.15 mg of levonosgestrel and 0.03 mg of ethynil estradiol per day over 21 days.
Other Names:
|
ACTIVE_COMPARATOR: Nordette
pill comparator contained levonorgestrel 0,15 mg and ethynil estradiol 0,03 mg per day over 21 days
|
Administration of one pill contained 0.15 mg of levonosgestrel and 0.03 mg of ethynil estradiol per day over 21 days.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The primary efficacy endpoint will be the changes in FSH and LH secretion induced by daily administration of the drug for 21 consecutive days during the 28 days of participation in the trial.
Time Frame: 1, 2, 4, 7, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 24 and 28 days
|
1, 2, 4, 7, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 24 and 28 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Safety of drugs: type, frequency and intensity of adverse events between groups during the 28 day trial. Exploratory investigation of the pharmacokinetics of the drug administered through the dosage of hormones in serum LNG and EE2 for 28 days.
Time Frame: PK: 1 (0, 1, 2, 3, 4, 5, 6, 12 e 18 hours after administration), 2, 7, 14, 21 and 28 days
|
PK: 1 (0, 1, 2, 3, 4, 5, 6, 12 e 18 hours after administration), 2, 7, 14, 21 and 28 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Alexandre Frederico, PI, LAL Clínica Pesquisa e Desenvolvimento Ltda
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Twaddle NC, Churchwell MI, Newbold RR, Delclos KB, Doerge DR. Determination using liquid-chromatography-electrospray tandem mass spectroscopy of ethinylestradiol serum pharmacokinetics in adult Sprague-Dawley rats. J Chromatogr B Analyt Technol Biomed Life Sci. 2003 Aug 15;793(2):309-15. doi: 10.1016/s1570-0232(03)00331-3.
- Benagiano G, Carrara S, Filippi V. Safety, efficacy and patient satisfaction with continuous daily administration of levonorgestrel/ethinylestradiol oral contraceptives. Patient Prefer Adherence. 2009 Nov 3;3:131-43. doi: 10.2147/ppa.s3692.
- Crosignani PG, Testa G, Vegetti W, Parazzini F. Ovarian activity during regular oral contraceptive use. Contraception. 1996 Nov;54(5):271-3. doi: 10.1016/s0010-7824(96)00178-3.
- van Heusden AM, Fauser BC. Activity of the pituitary-ovarian axis in the pill-free interval during use of low-dose combined oral contraceptives. Contraception. 1999 Apr;59(4):237-43. doi: 10.1016/s0010-7824(99)00025-6.
- Rossmanith WG, Steffens D, Schramm G. A comparative randomized trial on the impact of two low-dose oral contraceptives on ovarian activity, cervical permeability, and endometrial receptivity. Contraception. 1997 Jul;56(1):23-30. doi: 10.1016/s0010-7824(97)00070-x.
- Hemrika DJ, Slaats EH, Kennedy JC, de Vries Robles-Korsen TJ, Schoemaker J. Pulsatile luteinizing hormone patterns in long term oral contraceptive users. J Clin Endocrinol Metab. 1993 Aug;77(2):420-6. doi: 10.1210/jcem.77.2.8345046.
- Kroll R, Reape KZ, Margolis M. The efficacy and safety of a low-dose, 91-day, extended-regimen oral contraceptive with continuous ethinyl estradiol. Contraception. 2010 Jan;81(1):41-8. doi: 10.1016/j.contraception.2009.07.003.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 2014
Primary Completion (ACTUAL)
April 1, 2015
Study Completion (ACTUAL)
June 1, 2015
Study Registration Dates
First Submitted
November 25, 2011
First Submitted That Met QC Criteria
November 28, 2011
First Posted (ESTIMATE)
November 29, 2011
Study Record Updates
Last Update Posted (ESTIMATE)
March 3, 2016
Last Update Submitted That Met QC Criteria
March 2, 2016
Last Verified
March 1, 2016
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Contraceptive Agents, Hormonal
- Contraceptive Agents
- Reproductive Control Agents
- Contraceptives, Oral, Combined
- Contraceptives, Oral
- Contraceptive Agents, Female
- Contraceptives, Oral, Synthetic
- Contraceptives, Oral, Hormonal
- Contraceptives, Postcoital, Synthetic
- Contraceptives, Postcoital
- Contraceptives, Postcoital, Hormonal
- Ethinyl Estradiol-Norgestrel Combination
Other Study ID Numbers
- LEEUNI0811
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
The study data will be maked available after journal's approbation.
The manuscript contained all of data it has been submitted.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Irregular Periods
-
AbbottCompletedIrregular Menstrual CycleKazakhstan, Russian Federation, Ukraine, Uzbekistan
-
AbbottCompletedIrregular Menstrual CycleIndia
-
Johnson & Johnson Medical, ChinaCompleted
-
Taipei Medical University WanFang HospitalCompletedIrregular Menstrual Cycle | Regular Menstrual CycleTaiwan
-
Eye Hospital Pristina KosovoActive, not recruiting
-
Assiut UniversityCompleted
-
Jennifer FogtContamac LtdCompleted
-
Penn State UniversityDairy Management Inc.CompletedDelayed Transit Time | Irregular Bowel FunctionUnited States
-
Emory UniversityChildren's Healthcare of AtlantaCompleted
-
AcuFocus, Inc.RecruitingCataract | Presbyopia | Irregular AstigmatismPhilippines, Singapore
Clinical Trials on LNG+EE2
-
BayerCompleted
-
BayerCompletedMenopauseBelgium, Netherlands, Finland, United Kingdom
-
United States Naval Medical Center, PortsmouthUnknownContraception | Postpartum PeriodUnited States
-
University of Texas Southwestern Medical CenterWithdrawnAdenomyosis | Abnormal Uterine Bleeding
-
AstraZenecaParexelCompleted
-
Assiut UniversityCompletedPregnancy During Breastfeeding | Lactational Amenorrhea Method
-
King Chulalongkorn Memorial HospitalCompleted
-
Organon and CoCompleted
-
Population CouncilCompletedFemale ContraceptionChile, Dominican Republic